echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Mov Disord: Xiangya Hospital: Neurofilament light chain protein can effectively predict ataxia

    Mov Disord: Xiangya Hospital: Neurofilament light chain protein can effectively predict ataxia

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hereditary ataxia is a group of clinically and genetically heterogeneous neurodegenerative diseases characterized by cerebellar ataxia caused by genetic mutations
    .


    It can be inherited in an autosomal dominant, autosomal recessive, X-linked or mitochondrial manner


    The most common subtypes of autosomal dominant ataxia are spinocerebellar ataxia types 1, 2, 3, 6 and 7 (SCA 1, 2, 3, 6 and 7), which are repeated by CAG in the causative gene Amplification (CAGexp) caused
    .

    Friedreich ataxia ataxia (FRDA) and ataxia capillary vascular ectasia (AT) is the most common autosomal recessive ataxia, respectively, by GAA FXN gene duplication extension (GAAexp) and mutated ATM gene causes
    .

    Blood vessel

    Currently, there is no effective treatment for hereditary ataxia to prevent the disease or prevent its development
    .


    The clinical need for reliable biomarkers for genetic ataxia has not been met


    prevention

    Currently, neurofilament light chain (NfL) has become one of the promising candidate biomarkers for diagnosis , progression, prognosis, and evaluation of treatment response to neurological diseases (such as Alzheimer's disease and Huntington's disease)
    .

    Neurofilament light chain (NfL) has become one of the promising candidate biomarkers for diagnosis , progression, prognosis, and evaluation of treatment response to neurological diseases (such as Alzheimer's disease and Huntington's disease)
    .


    diagnosis

    NfL is a neuron-specific cytoskeletal protein, especially expressed in large-caliber myelinated axons
    .


    It can be actively (for example, through exosomes) or passively released from neurons, secondary to axonal injury and loss of neuronal membrane integrity, enter the brain interstitium, and freely exchange with cerebrospinal fluid (CSF)


    In addition, the NfL flowing to the peripheral circulation is mediated by the arterial basement membrane to drain around the blood vessels, then drain into the neck or lumbar lymph nodes, and finally enter the blood
    .


    Ideally, it is a sensitive marker of nerve axis damage and can be detected in CSF and peripheral blood


    However, a comprehensive meta-analysis has not been conducted to evaluate the potential role of NfL as a biomarker in predicting the occurrence of disease or symptoms, measuring disease severity, tracking disease progression, and monitoring treatment response to genetic ataxia
    .

    Therefore, Linliu Peng and others of Xiangya Hospital conducted a meta-analysis and summarized the current scientific literature on cNfL and bNfL, including plasma NfL (pNfL) or serum NfL (sNfL) in hereditary ataxia
    .


    When using NfL levels as a biomarker for hereditary ataxia, this meta-analysis can provide clinical application value


    A meta-analysis was performed to summarize the current scientific literature on cNfL and bNfL, including plasma NfL (pNfL) or serum NfL (sNfL) in hereditary ataxia


    They found 11 studies involving 624 HC and 1006 patients, referring to spinocerebellar ataxia (SCA1, 2, 3, 6, and 7), Friedreich ataxia ataxia (FRDA), and ataxia Far Qu (AT)
    .


    The concentration of NfL in the blood (bNfL) increases as the expected onset time approaches, and gradually increases from asymptomatic to preclinical stage in SCA3


    In SCA3, there is a significant correlation between bNfL and longitudinal progression
    .

    In addition, in HC, bNfL increases with age, but this may be masked by the higher impact of disease-related bNfL in hereditary ataxia
    .

    The significance of this meta-analysis is the discovery: bNfL can be used as a potential biomarker to predict the incidence, severity and progression of hereditary ataxia
    .


    The reference value setting of bNfL should be divided according to age


    bNfL can be used as a potential biomarker to predict the incidence, severity and progression of hereditary ataxia

    Original source:
    Peng L, Wang S, Chen Z, et al.
    Blood Neurofilament Light Chain in Genetic Ataxia: A Meta-Analysis.
      Mov Disord.
    Published online September 14, 2021:mds.
    28783.
    doi:10.
    1002/mds.
    28783


    Blood Neurofilament Light Chain in Genetic Ataxia: A Meta-Analysis.
      Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.